Courtenay C. Brinckerhoff

Courtenay C. Brinckerhoff

Foley & Lardner LLP

Contact  |  View Bio  |  RSS

Latest Posts › Enablement Inquiries

Share:

The Value Of Prophetic Examples

In Allergan, Inc. v. Sandoz, Inc., the Federal Circuit affirmed the district court decision that upheld the validity of the Allergan patents relating to Lumigan® 0.01% glaucoma eye drops against obviousness, written...more

8/13/2015 - Allergan Inc Allergan v Sandoz Enablement Inquiries Inherency Obviousness Patent Infringement Patent Invalidity Patent Litigation Patents Prior Art Written Descriptions

Lumigan Patents Upheld by Unexpected Results

In Allergan, Inc. v. Sandoz, Inc., the Federal Circuit affirmed the district court decision that upheld the validity of the Allergan patents relating to Lumigan® 0.01% glaucoma eye drops. This decision shows that it is still...more

8/13/2015 - Allergan Inc Allergan v Sandoz Drug Manufacturers Enablement Inquiries Inherency Obviousness Patent Infringement Patent Invalidity Patent Litigation Patent Ownership Patents Pharmaceutical Manufacturers Pharmaceutical Patents Prior Art Written Descriptions

Federal Circuit Finds Wyeth Restenosis Claims Invalid as Not Enabled

In Wyeth v. Abbott Laboratories, the Federal Circuit affirmed the district court’s decision that the claims at issue are invalid for failing to satisfy the enablement requirement of 35 USC § 112....more

7/2/2013 - Abbott Laboratories Enablement Inquiries Patents Pharmaceutical Prescription Drugs Validity Wyeth

Challenging the Enabling Quality of Prior Art

In In re Morsa, the Federal Circuit reversed an anticipation rejection where the applicant had challenged the enabling quality of the cited prior art reference, even though the applicant had not submitted evidence in support...more

4/19/2013 - Enablement Inquiries Patent Applications Prior Art USPTO

Federal Circuit Upholds Fentora Patents, But Affirms Non-Infringement

In Cephalon, Inc. v. Watson Pharmaceuticals, Inc., the Federal Circuit reversed the district court’s finding that two Orange Book-listed patents for Cephalon’s FENTORA® product were invalid, but affirmed the district court’s...more

2/26/2013 - ANDA Cephalon Enablement Inquiries Infringement Noninfringement Patents Pharmaceutical Written Descriptions

5 Results
|
View per page
Page: of 1

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:

Sign up to create your digest using LinkedIn*

*With LinkedIn, you don't need to create a separate login to manage your free JD Supra account, and we can make suggestions based on your needs and interests. We will not post anything on LinkedIn in your name. Or, sign up using your email address.
×